Oric Pharmaceuticals, Inc.
Developing therapies to overcome resistance in lung and prostate cancer.
ORIC | NDAQ
Overview
Corporate Details
- ISIN(s):
- US68622P1093
- LEI:
- Country:
- United States of America
- Address:
- 240 E. GRAND AVE., 94080 SOUTH SAN FRANCISCO
- Website:
- https://oricpharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to overcome cancer resistance. The company's scientific platform targets the primary mechanisms of therapeutic resistance—innate, acquired, and bypass—to improve the efficacy and duration of clinical benefit for patients. Oric's pipeline features targeted therapies in clinical development, including enozertinib (ORIC-114) for non-small cell lung cancer (NSCLC) with EGFR/HER2 mutations and ORIC-944 for prostate cancer, addressing significant unmet needs in oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Oric Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oric Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oric Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
